Italy Radiotherapy Market Overview, 2031

Key Insights

• The Italian radiotherapy market operates within the Servizio Sanitario Nazionale, a publicly funded healthcare system that ensures universal access to radiation oncology services. Cancer remains a leading cause of mortality in Italy, with radiotherapy playing a central role in curative and palliative treatment for approximately 50% of all cancer patients.
• External Beam Radiotherapy (EBRT) constitutes the largest therapy segment, supported by an installed base of approximately 390 linear accelerators across Italian radiotherapy centres . IMRT and IGRT techniques are standard across the majority of centres, with advanced stereotactic systems including Cyberknife, TomoTherapy, and Novalis deployed in specialised facilities.
• Radiotherapy systems and equipment represent the largest offering segment, with the market characterised by significant public investment through the Piano Nazionale di Ripresa e Resilienza. Consip has launched framework agreements for 62 linear accelerators valued at approximately €130 million as part of the PNRR modernisation programme . Major equipment suppliers include Elekta, Varian Medical Systems, and Accuray.
• Hospitals and integrated cancer centres are the largest end-user segment, operating within the public hospital system. However, significant regional disparities exist: equipment density ranges from one accelerator per 102,000 inhabitants in Friuli-Venezia Giulia to one per 282,000 inhabitants in Calabria . Approximately 71% of accelerators are located in public healthcare facilities, with 27.7% in accredited private hospitals .
• Regulatory oversight is provided under Legislative Decree 101/2020, which transposes EU Directive 2013/59/Euratom and establishes quality assurance requirements, medical physics involvement, and radiation protection standards. The decree mandates the involvement of medical physics specialists in radiotherapy procedures and requires quality management systems including clinical audit programmes .

Market Outlook

• According to the research report, "Italy Radiotherapy Market Overview, 2031," published by Bonafide Research, the Italy Radiotherapy Market is expected to reach a market size of more than USD 390 Million by 2031. This growth trajectory reflects sustained public investment through the PNRR, technology modernisation, and increasing cancer burden across the aging population.
• The market is expected to benefit from significant government investment in equipment renewal. Consip has launched a framework agreement for 62 new linear accelerators and systems for radiotherapy including respiratory gating, patient positioning control, and in-vivo dosimetry valued at approximately €130 million . These acquisitions are financed through PNRR funds under Mission 6 (Health), Component 2 "Innovation, research and digitalisation of the NHS," Investment 1.1 "Modernisation of the hospital technological and digital fleet" .
• Technology adoption is accelerating across Italian radiotherapy centres. The AIRO Super project, a voluntary survey of 135 of 185 invited centres, has documented the diffusion of modern techniques including IMRT, IGRT, and stereotactic radiotherapy. The proportion of centres with multiple platforms (two or three accelerators) approaches 70%, enabling continuity of service during equipment maintenance . Recent investments include the Radixact system at the Perugia Radiotherapy Centre, a €6.3 million installation with 89-day preparation and installation timeline .
• The market is also characterised by significant regional disparities in equipment distribution and access. While the national average of 144,000 inhabitants per treatment unit compares favourably to the European average of 180,000, regional variation is substantial from 102,000 inhabitants per unit in Friuli-Venezia Giulia to 282,000 in Calabria . This variation creates opportunities for infrastructure expansion in underserved regions, particularly in Southern Italy and the islands.
• Long-term growth is supported by demographic trends and workforce renewal. The PNRR investment in technology renewal must be accompanied by workforce development, with radiologists noting that the average age of medical personnel in Italian hospitals is 57 years and that generational renewal is a critical priority .

Market Dynamics

Driver: Sustained Public Investment through PNRR and Consip Procurement
The primary driver of the Italian radiotherapy market is sustained public investment through the Piano Nazionale di Ripresa e Resilienza and centralised procurement mechanisms. Consip, the Italian public procurement agency, has launched framework agreements for 62 linear accelerators valued at approximately €130 million the first time radiotherapy equipment has been the subject of a Consip framework agreement . These initiatives are part of the broader PNRR investment of €3.41 billion for 2,648 large healthcare equipment items and digitalisation of 184 hospital facilities . The framework agreements, developed in collaboration with scientific societies including AIRO (Italian Association of Radiotherapy and Clinical Oncology) and AIFM (Italian Association of Medical Physics), ensure that equipment meets the latest clinical and technical standards. The instrument of the framework agreement with multiple awardees with duration of one year plus up to six months extension guarantees the widest choice for public administrations while achieving cost efficiencies through centralised purchasing .

Challenge: Regional Disparities and Infrastructure Constraints
A significant challenge facing the Italian radiotherapy market is the substantial regional disparity in equipment availability and access to care. The AIRO Super project survey has documented wide variation in equipment density, ranging from one linear accelerator per 102,000 inhabitants in Friuli-Venezia Giulia to one per 282,000 inhabitants in Calabria . The proportion of centres with a single treatment platform approaches and exceeds 20% in Southern Italy, meaning that in the event of equipment failure, one in five centres would be forced to suspend activities resulting in either overloading of neighbouring hospitals or lengthening of waiting lists . Equipment obsolescence remains a concern, particularly in Southern Italy where approximately 34% of accelerators have been in operation for more than ten years, though this is an improving indicator reflecting the impact of PNRR investment . The lack of systematic monitoring of installed equipment has historically complicated infrastructure planning, with estimates of the installed base ranging from 340 to 419 LINACs from different sources .



Trend: Technology Modernisation and Precision Radiotherapy Adoption
A major trend shaping the Italian radiotherapy market is the acceleration of technology modernisation through PNRR investment and the adoption of precision radiotherapy techniques. The Consip framework agreement for 62 linear accelerators includes advanced features including respiratory gating, patient positioning control, and in-vivo dosimetry, reflecting the shift toward image-guided and adaptive radiotherapy . Recent installations demonstrate the diffusion of cutting-edge technology: the Perugia Radiotherapy Centre has installed a Radixact system, a €6.3 million investment that integrates a linear accelerator with CT imaging and real-time organ motion control, enabling ablative radiotherapy for lung, prostate, head and neck, and paediatric cancers, as well as TMLI for haematological malignancies . The Lazio Region has invested €2.2 million in a new linear accelerator for the Latina hospital, replacing an obsolete Saturno 41 system that had been out of production for years . The Sicilian Region has allocated €760,000 for replacement of a Varian Clinac IX at the Ragusa hospital . This modernisation trend is driving demand for new equipment, installation services, training, and comprehensive maintenance contracts.

Policies

• Legislative Decree 101/2020 transposes EU Council Directive 2013/59/Euratom into Italian law, establishing the regulatory framework for radiation protection in medical exposures. The decree mandates medical physics specialist involvement in radiotherapy procedures, quality assurance requirements, and clinical audit programmes .
• Article 164 of Legislative Decree 101/2020 requires the Responsible for the Radiological Installation to prepare a Quality Manual including: inventory of equipment subject to quality control, modalities for recording radiological investigations, acceptance testing and frequency of verification, adopted reference diagnostic levels, and analysis of accidental and unintended exposure scenarios .
• The Consip framework agreement for 62 linear accelerators, developed in collaboration with AIRO and AIFM, represents the first centralised procurement initiative for radiotherapy equipment. The agreement uses the "economically most advantageous offer" criterion with 80 technical points and 20 economic points, with technical evaluation including technical reports and video-demonstrations .
• The AIRO Super project, a voluntary survey of radiotherapy centres, provides critical data on equipment availability, treatment techniques, and regional disparities. The project's ongoing work in 2025 and 2026 aims to update available responses, involve additional centres, and refine information granularity .
• The PNRR Mission 6, Component 2, Investment 1.1 "Modernisation of the hospital technological and digital fleet" provides funding for equipment replacement, including the Consip framework agreements for linear accelerators and gamma cameras .
• The Italian Association of Radiotherapy and Clinical Oncology and the Italian Association of Medical Physics provide professional standards, quality assurance protocols, and clinical practice guidelines that shape technology adoption and treatment delivery patterns across Italian radiotherapy centres .
• Legislative Decree 101/2020 establishes professional requirements for radiotherapy practice: medical specialists in radiotherapy must be graduates in medicine and surgery with specific specialisation, medical physics specialists must be graduates in physics with specialisation, and radiographers must hold appropriate qualifications and be registered with the relevant professional order .

Segment Analysis

Italy Radiotherapy Market By Therapy Type
• External Beam Radiotherapy (EBRT): This is the largest therapy segment, reflecting the widespread installed base of approximately 390 linear accelerators across Italian radiotherapy centres . Approximately 70% of centres operate two or three external beam treatment machines, enabling continuity of service during maintenance . The installed base includes conventional LINACs as well as dedicated stereotactic systems including Cyberknife, TomoTherapy, and Novalis. IMRT has become nearly universal, with advanced techniques including IGRT, VMAT, and SBRT widely adopted. Recent installations such as the Radixact system at Perugia demonstrate the diffusion of integrated imaging and adaptive radiotherapy platforms .
• Internal / Brachytherapy: This segment remains clinically essential, particularly for prostate, gynaecological, breast, and head and neck cancers. Brachytherapy services are concentrated in specialised centres with dedicated medical physics support. Equipment procurement for brachytherapy is included in broader radiotherapy equipment modernisation programmes.
• Systemic Radiotherapy: This is the fastest-growing therapy segment, driven by the emergence of novel radiopharmaceuticals and targeted radionuclide therapies. The segment benefits from Italian academic research institutions and clinical trial infrastructure. Legislative Decree 101/2020 provides specific provisions for administration of radioactive substances for treatment or diagnosis, with medical physics specialist involvement required for therapy procedures .

Italy Radiotherapy Market By Offering
• Radiotherapy Systems/Equipment: This segment holds the largest market share by revenue, driven by the high capital cost of linear accelerators and substantial PNRR investment. Consip's framework agreement for 62 linear accelerators valued at approximately €130 million represents a significant procurement initiative . Major equipment suppliers active in the Italian market include Elekta, Varian Medical Systems (recent installations include Varian TrueBeam and Halcyon platforms), and Accuray (Cyberknife, TomoTherapy, Radixact) . Recent investments demonstrate substantial capital expenditure: the Perugia Radixact installation cost €6.3 million , the Latina hospital investment was €2.2 million , and the Ragusa hospital investment was €760,000 . Equipment renewal cycles and technology modernisation drive sustained demand.
• Software & Services: This is the fastest-growing segment, reflecting increasing digitalisation of radiation oncology. The software component includes advanced treatment planning systems the Perugia Radixact system integrates CT imaging with real-time organ motion control and oncology information systems. The services component encompasses installation, comprehensive maintenance, clinical training, physics support, and technical support. Consip framework agreements include requirements for equipment complete with accessories and implementation of treatment plans . The trend toward precision radiotherapy and adaptive treatments drives software and services demand.

Italy Radiotherapy Market By Application
• Breast Cancer: This is a major application segment, with breast cancer ranking among the most frequent malignancies in Italy. Radiotherapy plays a central role in breast-conserving therapy and post-mastectomy treatment. Hypofractionation protocols are widely adopted to optimise treatment efficiency and patient convenience.
• Prostate Cancer: A significant application area, with widespread use of EBRT, SBRT, and brachytherapy. Italian radiation oncology departments offer advanced prostate cancer treatment with image guidance and real-time tracking. The Radixact system at Perugia is particularly indicated for prostate cancer .
• Lung Cancer: This segment is growing, with increased adoption of SBRT for early-stage and oligometastatic disease. The Radixact system at Perugia is particularly effective for lung cancer, enabling high-dose ablative radiotherapy with real-time motion management .
• Head & Neck Cancer: This is a critical application due to anatomical complexity, requiring highly conformal radiation delivery. IMRT is the standard of care, and this segment drives adoption of advanced image-guided and adaptive radiotherapy platforms. The Radixact system at Perugia is indicated for head and neck cancers .
• Central Nervous System / Brain: This is a significant application, with stereotactic radiosurgery for brain metastases and primary CNS tumours. Italian centres with dedicated stereotactic systems offer advanced CNS treatments.
• Gastro-intestinal: Applications include oesophageal, rectal, liver, and pancreatic cancers. The Radixact system at Perugia enables treatment of multiple sites simultaneously .
• Other Applications: Includes haematological malignancies the Perugia centre has developed TMLI for bone marrow transplant preparation, enabling transplants in patients over 70 years and dose escalation in non-remission patients as well as gynaecological, paediatric, and palliative care indications. Paediatric cancers benefit from the precision of modern systems in sparing healthy tissues .

Italy Radiotherapy Market By End User
• Hospitals & Integrated Cancer Centres: This is the largest end-user segment, operating within the public hospital system. Approximately 71% of linear accelerators are located in public healthcare facilities . Major centres including the Perugia Radiotherapy Centre (which inaugurated a Radixact system with the Minister of Health present) , the Fondazione Policlinico Gemelli in Rome , and the Goretti Hospital in Latina represent the forefront of technology adoption. These institutions manage the most complex equipment fleets and are the primary beneficiaries of PNRR and Consip procurement programmes.
• Standalone Radiotherapy Centres: This segment includes accredited private hospitals, which account for approximately 27.7% of installed accelerators . Private healthcare providers are modernising their equipment fleets, representing a growth area for both capital equipment and service contracts.
• Academic/Research Institutions: This is the fastest-growing segment, reflecting their central role in advancing the field through clinical trials and technology validation. Academic centres including the Perugia centre (which participates in international clinical research and has developed TMLI technique) and other university hospitals are at the forefront of innovation and technology adoption.
• Other Healthcare Facilities: Includes community hospitals and palliative care facilities. The AIRO Super project documented that over half of radiotherapy structures perform 70-80% of curative radiotherapy treatments in Italy, including in Southern Italy and the Islands .

Italy Radiotherapy Market Economics

• Equipment procurement in Italy is predominantly conducted through public tenders and Consip framework agreements, which achieve significant cost efficiencies through centralised purchasing. The Consip framework for 62 linear accelerators is valued at approximately €130 million .
• Multi-year contracts are standard, with the Consip framework agreement lasting one year from activation plus potential six-month extension, enabling predictable maintenance costs and technology lifecycle management .
• The economic value of radiotherapy is well-recognised in Italy, with modern technology reducing patient transports, enabling hypofractionation, and contributing to healthcare system efficiency. The AIRO Super project has documented the importance of multiple platforms per centre (two or three accelerators in approximately 70% of centres) to manage equipment downtime without interrupting service .
• Regional economic disparities are significant: the national average of 144,000 inhabitants per treatment unit compares favourably to Europe, but the range from 102,000 in Friuli-Venezia Giulia to 282,000 in Calabria illustrates profound inequalities . Equipment density variation exists even within regions, such as Cuneo province with one accelerator per 300,000 inhabitants and nearby Aosta Valley with one TomoTherapy per 120,000 inhabitants .
• The economic impact of PNRR investment is substantial: the €3.41 billion programme for 2,648 large healthcare equipment items includes significant allocation for radiotherapy equipment . Recent investments include €6.3 million for Perugia Radixact , €2.2 million for Latina , and €760,000 for Ragusa .
• Equipment downtime directly affects patient access, treatment schedules, and clinical outcomes. In centres with a single accelerator (approaching and exceeding 20% in Southern Italy), equipment failure results in suspension of activities, overloading neighbouring centres, or lengthening of waiting lists .
• Workforce economics present a significant challenge: the average age of medical personnel in Italian hospitals is 57 years, with generational renewal a critical priority. The PNRR investment in technology must be accompanied by workforce development to ensure effective equipment utilisation .

Market Outlook by Infrastructure, Investment and Industry Development

• The Consip framework agreement for 62 linear accelerators, developed in collaboration with AIRO and AIFM, represents the largest centralised procurement initiative for radiotherapy equipment in Italian history. The agreement covers linear accelerators and systems for radiotherapy including respiratory gating, patient positioning control, and in-vivo dosimetry .
• The PNRR Mission 6, Component 2, Investment 1.1 "Modernisation of the hospital technological and digital fleet" provides the funding framework for equipment renewal. The programme includes acquisition and commissioning of 2,648 large healthcare equipment items and digitalisation of 184 hospital facilities with a total investment of €3.41 billion .
• Recent technology installations demonstrate the pace of modernisation: the Perugia Radiotherapy Centre inaugurated a Radixact system with a €6.3 million investment, featuring 89-day installation timeline and capacity to treat 25 patients daily across a 12-hour shift . The Lazio Region invested €2.2 million for a new linear accelerator at Latina . The Sicilian Region allocated €760,000 for accelerator replacement at Ragusa .
• The AIRO Super project continues its work through 2025 and 2026 to update available data, involve additional centres, and refine information on radiotherapy equipment and treatment patterns across Italy . This data collection will support evidence-based infrastructure planning.
• Digital transformation is enabling remote diagnostics, predictive maintenance, and real-time performance monitoring of radiotherapy equipment. The adoption of AI in healthcare already advanced in some European countries is progressing more slowly in Italy, with industry calling for a national institutional table by 2026 to define evaluation and reimbursement rules for AI-based medical devices .
• Workforce development is a critical priority. The average age of medical personnel in Italian hospitals is 57 years, and while younger radiologists are capable of using modern equipment, recruitment remains a challenge particularly in the public sector, where younger professionals are attracted to the private market . The radiology sector has noted that equipment renewal without accompanying staff recruitment is like "having a luxury car without an expert driver" .
• The long-term outlook remains positive as cancer incidence continues to rise, technology innovation accelerates, and public investment through PNRR and Consip sustains equipment modernisation. However, addressing regional disparities and workforce constraints will be essential to ensuring equitable access to advanced radiotherapy across all Italian regions.



Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Radiotherapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• External Beam Radiotherapy (EBRT)
• Internal / Brachytherapy
• Systemic Radiotherapy

By Offering
• Radiotherapy Systems/Equipment
• Software & Services

By Application
• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Head & Neck Cancer
• Central Nervous System / Brain
• Gastro-intestinal
• Other Applications

By End User

• Hospitals & Integrated Cancer Centers
• Standalone Radiotherapy Centers
• Academic/Research Institutions
• Other Healthcare Facilities